Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

A method of producing an autologous anti-inflammatory/anti-catabolic autologous composition useful in the treatment of a mammal suffering from damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears, chronic degenerative joint conditions, and/or skin inflammatory disorders is provided. The method comprising the following steps: delivering a blood collected from the mammal to a tube; storing the blood in presence of sodium citrate at a temperature of from about 20° C. to about 40° C. for at least about 3.5 hours; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.

A method of producing an autologous anti-inflammatory/anti-catabolic autologous composition useful in the treatment of a mammal suffering from damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears, chronic degenerative joint conditions, and/or skin inflammatory disorders is provided. The method comprising the following steps: delivering a blood collected from the mammal to a tube; storing the blood in presence of sodium citrate at a temperature of from about 20° C. to about 40° C. for at least about 3.5 hours; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.